NCT03510546

Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 44 (estimated)
• Sponsor: University of Aarhus · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

A randomized, placebo-controlled, double-blinded cross-over study evaluating and quantifying the effect of pyridostigmine on muscle strength and symptoms in Myasthenia Gravis (MG)

Detailed description

The study aims to evaluate and quantify the effect of pyridostigmine on symptoms and muscle strength in newly-diagnosed patients and patients on stable medication. Pyridostigmine treatment is initiated in the vast majority of MG patients. No studies have quantified the effect in a randomized trial, and no studies have examined the potential difference in effect in newly diagnosed patients as compared to patients on stable, antimyasthenic medications. The study will investigate the effect in two groups 1. Newly diagnosed, treatment-naive patients. 2. MG patients on stable antimyasthenic medication.

Conditions

• Myasthenia Gravis

Interventions

Type	Name	Description
DRUG	Pyridostigmine	Study dose as per protocol.
DRUG	Placebo oral capsule	Study dose as per protocol.

Timeline

• Start date: 2018-04-09
• Primary completion: 2020-08-31
• Completion: 2021-08-31
• First posted: 2018-04-27
• Last updated: 2018-04-27

Locations

1 site across 1 country: Denmark